
Amgen (AMGN) Stock Forecast & Price Target
Amgen (AMGN) Analyst Ratings
Bulls say
Amgen's 3Q25 financial performance demonstrated significant growth, with overall sales increasing by 40% compared to 3Q24 and 16 products achieving double-digit growth, highlighted by Repatha's 40% rise in worldwide sales. The company's revenue guidance for FY25 was recently adjusted upward to a range of $35.8 billion to $36.6 billion, indicating strong momentum across its established product franchises, particularly in oncology and rare diseases following strategic acquisitions. Additionally, the increased investment in R&D, projected to grow over 20% in 2025, further positions Amgen for future innovation and sustained financial strength in the biotechnology sector.
Bears say
Amgen's revenue growth is projected to be approximately 1% in 2026 compared to 2025, significantly impacted by anticipated sales declines of around 28% for Prolia and 39% for Xgeva. While the company possesses emerging products in its pipeline, such as MariTide and olpasiran, there is limited visibility on their potential to counterbalance the erosion of revenue from established products due to impending loss of exclusivity. Additionally, management's indication of muted R&D growth relative to prior years raises concerns about the company's ability to develop new long-term growth drivers in the face of these structural challenges.
This aggregate rating is based on analysts' research of Amgen and is not a guaranteed prediction by Public.com or investment advice.
Amgen (AMGN) Analyst Forecast & Price Prediction
Start investing in Amgen (AMGN)
Order type
Buy in
Order amount
Est. shares
0 shares